C) Page 3, lines 133-134: “Patients were then divided into two groups according to the drugs employed in antithrombotic chemoprophylaxis:” How was it decided which patients received which form of prophylaxis?
In the Abstract you state that “two patients during their course of Rivaroxaban presented severe hematoma”, but in Table 1 it appears that the two hematomas occurred in the enoxaparin group? Please clarify.